Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04271306
Other study ID # VAC082
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 25, 2021
Est. completion date March 2023

Study information

Verified date June 2022
Source University of Oxford
Contact Angela Minassian
Phone +44865611425
Email angela.minassian@ndm.ox.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase Ib age de-escalation and dose escalation open label clinical trial of the safety, immunogenicity and ex-vivo efficacy of a candidate malaria vaccine Pfs25-IMX313/Matrix-M administered intramuscularly in healthy adults and young children in Tanzania


Description:

This study aims to evaluate safety, immunogenicity, and transmission blocking activity of Pfs25IMX313-Matrix-M in healthy Tanzanian adults and children naturally exposed to malaria in Bagamoyo district, Tanzania. The study will enrol 45 volunteers comprising of 13 adults (18-45 years) and 32 children (5-12 years).


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date March 2023
Est. primary completion date March 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy adult aged 18 to 45 years or children aged 5-12 years. 2. Planned long-term (at least 30 months from the date of recruitment) or permanent residence in Bagamoyo town. 3. Adults with a Body Mass Index (BMI) 18 to 30 Kg/m2; or children (5-12 years) with the BMI between 13 and 25 Kg/m2. 4. Able and willing (in the Investigator's opinion) to comply with all study requirements. 5. Agreement to refrain from blood donation for the duration of the study 6. Written informed consent to participate in the trial. 7. Women only: Must practice continuous effective contraception* for the duration of the study. Exclusion Criteria: 1. Use of immunoglobulins or blood products (e.g., blood transfusion) at any time in the past. 2. Receipt of any vaccine in the 14 days preceding enrolment, or planned receipt of any other vaccine within 14 days following each vaccination. 3. Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period. 4. Concurrent involvement in another clinical trial or planned involvement during the study period 5. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator 6. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). 7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg products) 8. Any history of anaphylaxis in reaction to vaccinations 9. Pregnancy, lactation or intention to become pregnant during the study. 10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). 11. History of serious psychiatric condition that may affect participation in the study. 12. Any other serious chronic illness requiring hospital specialist supervision. 13. Suspected or known injecting drug abuse in the 5 years preceding enrolment. 14. Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV IgG). 15. Volunteers unable to be closely followed for social, geographic or psychological reasons. 16. Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of clinically significant abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria will be described in a study specific SOP. 17. Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Pfs25-IMX313 (10ug)/Matrix-M (50ug)
3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
Pfs25-IMX313 (50ug)/Matrix-M (50ug)
3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)
2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)

Locations

Country Name City State
Tanzania Ifakara Health Institute Clinical Trial Facility Bagamoyo

Sponsors (2)

Lead Sponsor Collaborator
University of Oxford Ifakara Health Institute

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the safety of Pfs25IMX313-Matrix-M in healthy Tanzanian adults and children naturally exposed to malaria. Occurrence of solicited symptoms after each vaccination during a 7-day surveillance period (day of vaccination and days 1, 2, 3 and 7 after vaccination). Assessment of solicited symptoms in the first 7 days post vaccination
Primary Determine the safety of Pfs25IMX313-Matrix-M in healthy Tanzanian adults and children naturally exposed to malaria. Occurrence of unsolicited symptoms after each vaccination during a 30-day surveillance period (day of vaccination and 30 subsequent days). Assessment of unsolicited symptoms in the first 30 days post vaccination
Primary Determine the safety of Pfs25IMX313-Matrix-M in healthy Tanzanian adults and children naturally exposed to malaria. Occurrence of serious adverse events throughout the study period. Assessment of SAEs until the end of the study (approx 2 years)
Secondary Determine the Pfs25 specific antibody responses following immunization with different vaccination regimens in healthy Tanzanian adults and children. Pfs25 antibody levels elicited by Pfs25IMX313-Matrix-M as measured by ELISA at each time point where serology samples are analysed. Duration of the study (approx 2 years)
Secondary Determine the transmission blocking activity of Pfs25 specific antibodies elicited by the different vaccination regimens in healthy Tanzanian adults and children using Standard Membrane Feeding Assay (SMFA) and Direct Membrane feeding assay (DMFA). Transmission blocking activity (TBA) of induced antibody as measured in standard membrane feeding assays (SMFA) and Direct Membrane feeding assays (DMFA). Duration of the study (approx 2 years)
Secondary Determine the transmission blocking activity of Pfs25 specific antibodies elicited by the different vaccination regimens in healthy Tanzanian adults and children using Standard Membrane Feeding Assay (SMFA) and Direct Membrane feeding assay (DMFA). Correlation of TBA with antibody levels at each time point where the membrane feeding assays are conducted. Duration of the study (approx 2 years)
Secondary Select the best vaccination regimen based on the peak Pfs25 specific antibodies after final immunization, their duration and transmission blocking activity by standard membrane feeding assay (SMFA) and direct membrane feeding assay (DMFA). The vaccination schedule that lead to the highest peak and duration of anti-Pfs25 antibody response post vaccination, and the highest transmission blocking activity (TBA) as measured by standard membrane feeding assay (SMFA) and direct membrane feeding assay (DMFA). Duration of the study (approx 2 years)
See also
  Status Clinical Trial Phase
Terminated NCT04130282 - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Phase 1
Completed NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Phase 2/Phase 3
Active, not recruiting NCT03814616 - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections Phase 2
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali Phase 1
Not yet recruiting NCT06083688 - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Phase 4
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Completed NCT05550909 - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Phase 2
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed NCT05081089 - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali Phase 2
Recruiting NCT05150808 - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania Phase 3
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Completed NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde Phase 4
Completed NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso Phase 1/Phase 2
Completed NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT04862416 - Safety and Efficacy of R0.6C Vaccine Phase 1